Effect of Nonnicotine Pharmacotherapy on Smoking Behavior

• Published in: Pharmacotherapy Vol. 21; no. 12; pp. 1530 - 1548
• Main Authors: Kotlyar, Michael, Golding, Michael, Hatsukami, Dorothy K., Jamerson, Brenda D.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-12-2001; Pharmacotherapy
• Subjects: Amphetamines - therapeutic use; Biological and medical sciences; Bupropion - therapeutic use; Clonidine - therapeutic use; Doxepin - therapeutic use; Humans; Medical sciences; Naltrexone - therapeutic use; Nortriptyline - therapeutic use; Serotonin Uptake Inhibitors - therapeutic use; Smoking Cessation - methods; Tobacco, tobacco smoking; Toxicology; Human; Agonist; Poison withdrawal; Serotoninergic transmission; Toxicity; Opioid receptor; Tobacco smoking; Review; Long term; Dopaminergic transmission; Alkaloid; Chemotherapy; Treatment; Noradrenergic transmission; Antagonist; Neurotransmission; Nicotine
• ISSN: 0277-0008; 1875-9114
• DOI: 10.1592/phco.21.20.1530.34477

Smoking‐related disease is the single biggest preventable cause of morbidity and mortality in the United States, yet approximately 25% of Americans continue to smoke. Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1‐year quit rates of over 20%. To increase these rates, a number of nonnicotine agents have been investigated. Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters.